AstraZeneca expands cancer trials as analysts rate AstraZeneca stock Moderate Buy

Published on 10/05/2026 at 11:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AstraZeneca enters a Summit collaboration for a Phase III cancer trial. AstraZeneca stock costs EUR 140.60 on October 5, 2026, plus 0.69 percent versus EUR 139.63.

Bauhaus-Poster mit Formen, Molekülstruktur, DNA-Helix und Schriftzug PHARMA — AstraZeneca plc (ISIN GB0009895292) zählt zu den weltweit größten Unternehmen der forschenden Pharmaindustrie und Biotechnologie, Illustration mit AI erstellt.

AstraZeneca (ISIN GB0009895292) was trading at EUR 140.60 at Lang & Schwarz on October 5, 2026 at 11:14 a.m. CEST, up 0.69 percent versus the prior close of EUR 139.63. On October 2, AstraZeneca and Daiichi Sankyo announced a clinical collaboration with Summit Therapeutics to test Datroway with ivonescimab across several cancer types, while MarketBeat reported a Moderate Buy consensus for the stock.

Summit deal targets Phase III

According to FinanzNachrichten on October 2, 2026, the companies intend to begin a Phase III trial in first-line triple-negative breast cancer. Each party will contribute its respective medicine, share trial costs and retain development and commercial rights.

The agreement broadens AstraZeneca's antibody-drug conjugate strategy beyond Datroway monotherapy. The planned combination pairs Datroway, a TROP2-directed treatment, with Summit's ivonescimab, which targets PD-1 and VEGF pathways.

Revenue growth meets mixed expectations

MarketBeat reported that AstraZeneca generated USD 15.38 billion in revenue in the second quarter of 2026, up 6.40 percent from the same period a year earlier. Quarterly earnings per share reached USD 2.63, exceeding the USD 2.50 consensus estimate, while revenue came in below the USD 15.44 billion estimate.

That combination gives the cancer collaboration a measurable commercial backdrop: revenue growth remains positive, but the revenue shortfall against consensus keeps execution central to the investment case. AstraZeneca's late-stage oncology pipeline therefore matters alongside near-term sales delivery.

Analysts see a Moderate Buy

MarketBeat said seven analysts covered AstraZeneca with six Buy ratings and one Hold rating, producing an average 12-month target of GBP 150.00. The same report listed targets from GBP 117.00 to GBP 178.00, putting the analyst view above the GBP 118.70 share price cited for the London listing.

The company also lists an October 12, 2026 management event at ASBMR and an October 26, 2026 management event at ESMO on its investor-relations page, giving investors two scheduled oncology-related dates after the collaboration announcement.

Euro quote stays above EUR 140

AstraZeneca's market capitalization was USD 243.3 billion as of October 2, 2026, while its U.S.-listed shares had a USD 153.41 to USD 212.71 52-week range. The London Stock Exchange remains the primary venue for the ordinary shares identified by ISIN GB0009895292.

The further course of trading is shown by the continuously updated real-time quote of AstraZeneca stock.